ATE251911T1 - Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten - Google Patents

Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten

Info

Publication number
ATE251911T1
ATE251911T1 AT00951595T AT00951595T ATE251911T1 AT E251911 T1 ATE251911 T1 AT E251911T1 AT 00951595 T AT00951595 T AT 00951595T AT 00951595 T AT00951595 T AT 00951595T AT E251911 T1 ATE251911 T1 AT E251911T1
Authority
AT
Austria
Prior art keywords
treatment
skin diseases
containing compositions
inflammatory skin
soluble hla
Prior art date
Application number
AT00951595T
Other languages
English (en)
Inventor
Selim Aractingi
Edgardo Delfino Carosella
Jean Dausset
Daher Iman Khalil
Philippe Moreau
Pascale Paul
Nathalie Rouas-Freiss
Original Assignee
Commissariat Energie Atomique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat Energie Atomique filed Critical Commissariat Energie Atomique
Application granted granted Critical
Publication of ATE251911T1 publication Critical patent/ATE251911T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00951595T 1999-06-18 2000-06-16 Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten ATE251911T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9907736A FR2794977B1 (fr) 1999-06-18 1999-06-18 Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention
PCT/FR2000/001670 WO2000078337A1 (fr) 1999-06-18 2000-06-16 Compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau

Publications (1)

Publication Number Publication Date
ATE251911T1 true ATE251911T1 (de) 2003-11-15

Family

ID=9546968

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00951595T ATE251911T1 (de) 1999-06-18 2000-06-16 Löslische hla-g enthaltende zusammensetsungen zur behandlung entzündlichen hautkrankheiten

Country Status (10)

Country Link
EP (1) EP1189627B1 (de)
JP (1) JP2003508351A (de)
AT (1) ATE251911T1 (de)
CA (1) CA2377519C (de)
DE (1) DE60005952T8 (de)
DK (1) DK1189627T3 (de)
ES (1) ES2206286T3 (de)
FR (1) FR2794977B1 (de)
IL (2) IL147123A0 (de)
WO (1) WO2000078337A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2810047B1 (fr) * 2000-06-13 2004-04-02 Commissariat Energie Atomique Nouvelle isoforme d'hla-g et ses applications
WO2007011044A1 (ja) * 2005-07-15 2007-01-25 Kyushu University, National University Corporation ジスルフィド結合型hla-g二量体を含む医薬組成物及びジスルフィド結合型hla-g二量体の製造方法
KR101455878B1 (ko) 2006-11-15 2014-11-03 바스프 에스이 연질 폴리우레탄 발포체의 제조 방법
EP2184070A1 (de) 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Proteine und pharmazeutische Verwendungen davon
EP2184297A1 (de) * 2008-11-07 2010-05-12 Hla-G Technologies HLA-G-Polypeptide und pharmazeutische Verwendungen davon
EP2264067A1 (de) 2009-06-18 2010-12-22 Hla-G Technologies HLA-G alpha 1 Multimere und pharmazeutische Verwendung davon
WO2010150233A2 (en) 2009-06-25 2010-12-29 Commissariat A L'energie Atomique Et Aux Energies Alternatives Multimeric polypeptides of hla-g including at least two alpha3 domains and pharmaceutical uses thereof
US9045544B2 (en) * 2010-05-28 2015-06-02 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis
WO2018215340A1 (en) 2017-05-23 2018-11-29 Julius-Maximilians-Universität Würzburg Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation
CN114269372A (zh) 2019-06-27 2022-04-01 克里斯珀医疗股份公司 嵌合抗原受体t细胞和nk细胞抑制剂用于治疗癌症的用途
CA3145620A1 (en) * 2019-07-05 2021-01-14 Intellexon Gmbh Hla-h in medicine and diagnostics
WO2021260657A1 (en) 2020-06-26 2021-12-30 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717498B1 (fr) * 1994-03-18 1996-05-03 Commissariat Energie Atomique Transcrits du gène de CMH de classe I HLA-G et leurs applications.
JPH11503320A (ja) * 1995-04-07 1999-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｈｌａ−ｇ検出用抗体
CA2221687A1 (en) * 1997-02-05 1998-08-05 Smithkline Beecham Corporation Tumor necrosis related receptor, tr5
FR2760023B1 (fr) * 1997-02-21 2004-05-07 Commissariat Energie Atomique Cellules eucaryotes exprimant a leur surface au moins une isoforme d'hla-g et leurs applications

Also Published As

Publication number Publication date
IL147123A (en) 2010-06-30
DE60005952T2 (de) 2004-07-29
EP1189627B1 (de) 2003-10-15
JP2003508351A (ja) 2003-03-04
WO2000078337A1 (fr) 2000-12-28
CA2377519C (fr) 2011-09-27
IL147123A0 (en) 2002-08-14
EP1189627A1 (de) 2002-03-27
FR2794977B1 (fr) 2003-10-31
FR2794977A1 (fr) 2000-12-22
DK1189627T3 (da) 2004-02-16
CA2377519A1 (fr) 2000-12-28
DE60005952D1 (de) 2003-11-20
DE60005952T8 (de) 2004-11-04
ES2206286T3 (es) 2004-05-16

Similar Documents

Publication Publication Date Title
ATE308527T1 (de) Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60042611D1 (de) Verfahren zur behandlung von gefässerkrankungen, dxid auszeichnen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60005952T8 (de) Lösliche hla-g enthaltende zusammensetzungen zur behandlung entzündlicher hautkrankheiten
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE60021908D1 (de) Hydroxyeicosatetraenoatsalze, zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE60136748D1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
TR200200278T2 (tr) Kalsilitik bileşimler
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties